Abstract Polyclonal CD8+ CD45RClow/− Tregs are potent regulatory cells able to control
solid organ transplantation rejection and even induce tolerance. However, donor major …

Clinical trials of Treg therapy in transplantation are currently entering phases IIa and IIb, with
the majority of these employing polyclonal Treg populations that harbor a broad specificity …

CD4+ CD25 high FOXP3+ regulatory T cells (Tregs) are involved in graft-specific tolerance
after solid organ transplantation. However, adoptive transfer of polyspecific Tregs alone is …

Based on compelling evidence from a vast number of in vitro and in vivostudies, Tregs have
become an attractive cell population to treat or even prevent auto-and alloimmunity …

Tregs expressing chimeric antigen receptors (CAR-Tregs) are a promising tool to promote
transplant tolerance. The relationship between CAR structure and Treg function was studied …

Gene editing by homology-directed recombination (HDR) can be used to couple delivery of
a therapeutic gene cassette with targeted genomic modifications to generate engineered …

Regulatory T cells are critical for maintaining immune tolerance. Recent studies have
confirmed their therapeutic suppressive potential to modulate immune responses in organ …

Endowing chimeric antigen receptor (CAR) T cells with additional potent functionalities
holds strong potential for improving their antitumor activity. However, because potency could …

Down-regulation of immune responses by regulatory T (Treg) cells is an important
mechanism involved in the induction of tolerance to allo-antigens (Ags). Recently, a novel …

Cellular therapies with polyclonal regulatory T-cells (Tregs) in transplantation and
autoimmune diseases have been carried out in both animal models and clinical trials …